Sharemaestro Newsreel

What Johnson & Johnson (JNJ)'s Leadership Shift and Cancer Drug Priority Review Mean For Shareholders

Johnson & Johnson (JNJ) recently announced a leadership change in its Innovative Medicine sector with Jennifer Taubert's retirement and Tom Cavanaugh stepping in. This shift, combined with the FDA Priority Review for subcutaneous amivantamab in head and neck cancer, is expected to influence J&J's …

Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to …

Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck stock has almost doubled investors' money over the past five years, yet there …

Kevin Hern sells stocks in Organon & Co. and Versant Media Group

Representative Kevin Hern recently sold shares in Organon & Co. (OGN) and Versant Media Group, Inc. (VSNT) on August 5, 2026, with each transaction valued between $1,001 and $15,000. The sales involved stocks held by the Hern Family Revocable Trust and the Hern Family …

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested Pays Annually.

Johnson & Johnson (NYSE: JNJ) has increased its dividend for 64 consecutive years, a streak surpassed by only nine other publicly traded stocks. A $10,000 investment in J&J stock, at approximately $260 per share, would yield about $204 annually given its new annual dividend …

Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race

Novo Nordisk's stock slipped by approximately 1% after CEO Mike Doustdar reframed the obesity treatment market, emphasizing that it's not a winner-takes-all scenario against Eli Lilly. Doustdar highlighted Novo's strong position in the oral GLP-1 market with oral Wegovy and suggested that pills could …

Telstra Stock Slips as A$1 Billion Buyback Meets Profit Miss

This article first appeared on GuruFocus. Telstra Group (TLGPY), Australia's largest telecommunications provider, slipped 0.5% in Thursday's early Australian trading. The market's message was pretty clear: another giant buyback was not enough. Telstra unveiled a fresh A$1 billion repurchase program, but annual attributable profit …

Johnson & Johnson (JNJ) insider Duato plans sale of 123,291 shares

Johnson & Johnson insider Joaquin Duato has filed to sell 123,291 shares of common stock through Fidelity Brokerage Services on August 13, 2026. These shares were acquired via stock option exercise for cash. This planned sale follows a previous sale of 48,480 shares on …

Appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over delayed drug approvals

A federal appeals court has reinstated a $6.7 billion lawsuit against Bristol Myers Squibb, brought by UMB Bank on behalf of former Celgene shareholders. The suit alleges Bristol Myers deliberately delayed FDA approvals for three drugs, including the cancer therapy Breyanzi, to avoid payouts …

BIIB Upgraded by Wolfe Research -- Price Target Raised to $300

Wolfe Research has upgraded Biogen (BIIB) to "Outperform" and raised its price target to $300.00, reflecting increased confidence in the company's future. Despite this positive sentiment, GuruFocus considers the stock 8.2% overvalued with a GF Value™ of $194.85, and insider activity shows net selling. …

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above …

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters …

Can Asceniv Help ADMA Stock Combat IG Market Challenges?

ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases. The company currently markets three FDA-approved plasma-derived biologics: Asceniv (immune globulin intravenous – slra 10% liquid) …

Novo Nordisk Escalates Weight-Loss War With Eli Lilly

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead …

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely …

Sanofi: Information concerning the total number of voting rights and shares - July 2026

Sanofi has released information regarding its total number of voting rights and shares as of July 31, 2026. The French pharmaceutical company reported 1,207,773,393 issued shares, 1,336,308,574 real voting rights (excluding treasury shares), and 1,343,475,636 theoretical voting rights (including treasury shares). This disclosure adheres …

Senior GSK plc (GSK) leaders acquire Ordinary Shares through Share Reward Plan

Several senior leaders and one closely associated person at GSK plc acquired Ordinary Shares under the company's Share Reward Plan on August 11, 2026. The acquisitions were made on the London Stock Exchange at a price of £19.3496 per share, with most individuals acquiring …

The Sharpest Exchanges From ABBV’s Earnings Call

European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2

The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …

Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent

(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade …

European Equities Traded in the US Rise in Thursday Trading

European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion Silver Upgrade …

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story

In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting …

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the …

The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that …

Novartis Wins UK Court Challenge to Entresto Patent

Novartis has successfully defended its patent for the blockbuster heart drug Entresto in a UK court challenge. The article, published by MT Newswires, indicates this as a significant win for the pharmaceutical giant. Further details require a membership to the financial news platform.

CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications

WOONSOCKET, RI / ACCESS Newswire / August 13, 2026 / Originally published on CVS Health Company Newsroom CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients …

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite …

Grifols stock trades below $8 as investors weigh earnings outlook

Grifols stock is trading just under $8, with a market capitalization of $5.44 billion, as investors evaluate its recent earnings and future prospects in the plasma-derived therapies sector. Despite trading at a discount compared to peers, the stock is showing modest declines, indicating market …

Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope

Eli Lilly's shares are near a record high as the company files six lawsuits against alleged illegal sales of its experimental obesity drug, retatrutide. These legal actions aim to protect the drug's future market ahead of its planned U.S. submission in Q1 2027, given …

2 S&P 500 Stocks with Exciting Potential and 1 We Ignore

2 S&P 500 Stocks with Exciting Potential and 1 We Ignore The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal …

Can Keytruda Sustain Merck's Growth in the Second Half of 2026?

Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 …

Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent

Novartis has successfully defended its patent for the heart drug Entresto in a UK court against Accord Healthcare, a subsidiary of Intas Pharmaceuticals, which intended to launch a generic version. The High Court rejected Accord's claim that Novartis's patent was invalid, affirming the patent's …

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

Eli Lilly and Company LLY announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly's new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April. Foundayo (orforglipron) generated …

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business …

AimwellBio Publishes Investor Briefing on Acquired Trustr Intellectual Property Portfolio Valued at $10m Reinforcing Commitment to Transparency

Behavioral engagement technology carries documented institutional lineage spanning Oxford, the University of Vermont, Cornell, AMCP, and a Sanofi pilot program, as inventor Dr. Chris A. Jones joins AimwellBio's Board of Advisors and leads further expansion. MIAMI, FL / ACCESS Newswire / August 13, 2026 …